Hyperglycemia induces toll like receptor 4 expression and activity in mouse mesangial cells: Relevance to diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 8, 2012, Pages

  Kaur, Harmeet ^a   Chien, Alexander ^a   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Inflammation; Mesangial expansion; Pattern recognition receptors; Renal disease

Indexed keywords

CELL SURFACE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERGLYCEMIA; IN VITRO STUDY; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84867708435     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00319.2012     Document Type: Article

References (54)

1. Abrass CK. Diabetic nephropathy mechanisms of mesangial matrix expansion. West J Med 162: 318-321, 1995.
2. Banas MC, Banas B, Hudkins KL, Wietecha TA, Iyoda M, Bock E, Hauser P, Pippin JW, Shankland S, Smith K, Stoelcker B, Liu G, Grone HJ, Kramer BK, Alpers CE. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 19: 704-713, 2008.
3. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 430: 257-263, 2004.
4. Brosius FC 3rd, Khoury CC, Buller CL, Chen S. Abnormalities in signaling pathways in diabetic nephropathy. Expert Rev Endocrinol Metab 5: 51-64, 2010.
5. Caramori ML, Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 12: 273-282, 2003.
6. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes and prediabetes in the United States, US Department of Health and Human Services, Atlanta, GA. 2011. (http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf).
7. Chen JX, Stinnett A. Critical role of the NADPH oxidase subunit p47phox on vascular TLR expression and neointimal lesion formation in high-fat diet-induced obesity. Lab Invest 88: 1316-1328, 2008.
8. Coughlan MT, Cooper ME, Forbes JM. Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid Redox Signal 9: 331-342, 2007.
9. Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 33: 861-868, 2010.
10. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces Toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 57: 3090-3098, 2008.
11. Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 52: 1665-1668, 2009.
12. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR 4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93: 578-583, 2008.
13. Devaraj S, Glasser N, Griffen S, Wang-Polagruto J, Migeulino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55: 774-779, 2006.
14. Devaraj S, Jialal I, Yun JM, Bremer A. Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism 60: 256-259, 2011.
15. Devaraj S, Tobias P, Jialal I. Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 55: 441-445, 2011.
16. Devaraj S, Tobias P, Kasinath BS, Ramsamooj R, Afify A, Jialal I. Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol 31: 1796-1804, 2011.
17. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Prac Endocrinol Metab 4: 444-452, 2008.
18. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camilla Golgi Lecture 2007. Diabe-tologia 51: 1347-1355, 2008.
19. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 14: S254-S258, 2003.
20. Haneda M, Koya D, Isono M, Kikkawa R. Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14: 1374-1382, 2003.
21. Hoffman BB, Sharma K, Zhu Y, Ziyadeh FN. Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int 54: 1107-1116, 1998.
22. Hodgkinson CP, Laxton RC, Patel K, Te S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Atheroscler Thromb Vasc Biol 28: 2275-2281, 2008.
23. Jain SK, Rains JL. Toll-like receptor-4 and vascular inflammation in diabetes. Cytokine 55: 446-447, 2011.
24. Jialal I, Kaur H. The role of Toll-like receptors in diabetes-induced inflammation: implications for vascular complication. Curr Diab Rep. [Epub ahead of print]
25. Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, Hu MCT, Reddy MA, Natarajan R. Role of the Akt/FoxO3a in TGF-p1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol 17: 3325-3335, 2006.
26. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384, 2010.
27. Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, Matsumura T, Tokunaga H, Brownlee M, Araki E. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 52: 2570-2577, 2003.
28. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 50: 2041-2046, 1996.
29. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Ogawa Y, Imamaki H, Kawanishi T, Ishii A, Koga K, Mori KP, Kato Y, Sugawara A, Nakao K. Exacerbation of diabetic nephtopathy by hyperlipidemia is mediated by Toll-like receptor 4 in mice. Diabetologia 55: 2256-2266, 2012.
30. Li F, Yang N, Zhang L, Tan H, Huang B, Liang Y, Chen M, Yu X. Increased expression of the toll-like receptor 2 in rat diabetic nephropathy. Am J Nephrol 32:179-186, 2010.
31. Li H, Sun B. Toll-like 4 receptor 4 in atherosclerosis. J Cell Mol Med 11: 88-95, 2007.
32. Lin M, Yiu WH, Wu HJ, Chan LYY, Leung JCK, Au WS, Chan KW, Lai KN, Tang SCW. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 23:86-102, 2012.
33. Liu X, Ukai T, Yumoto H, Davey M, Goswami S, Gibson FC 3rd, Genco CA. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 196: 146-154, 2008.
34. Lu Z, Li Y, Jin J, Zhang X, Lopez-Virella MF, Huang Y. Toll-like receptor 4 activation in microvascular endothelial cells triggers a robust inflammatory response and cross talk with mononuclear cells via interleu-kin-6. Arterioscler Thromb Vasc Biol 32: 1696-1706, 2012.
35. Manabe E, Handa O, Naito Y, Mizushima K, Akagiri S, Adachi S, Takagi T, Kokura S, Maoka T, Yoshikawa T. Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell Biochem 103: 1925-1937, 2008.
36. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14: 1358-1373, 2003.
37. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155, 1984.
38. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001.
39. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduced atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101: 10679-10684, 2004.
40. Mishra R, Emancipator SN, Kern T, Simonson MS. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int 67: 82-93, 2005.
41. Mullic AE, Tobias PS, Curtiss LK. Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res 34: 193-209, 2006.
42. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR. Suppression substractive hybridization in dentifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274: 5830-5834, 1999.
43. Nymark M, Pussinen PJ, Tuomainen AM, Forsblum C, Groop PH, Lehto M, FinnDiane Study Group. Serum lipopolysaccharide activity is associated with the progression of kidney disease in Finnish patients with type 1 diabetes. Diabetes Care 32: 1689-1693, 2009.
44. Okazaki Y, Yamasaki Y, Uchida H, Okamoto K, Satoh M, Maruyama K, Maeshima Y, Sugiyama H, Suguya T, Kahihara N, Makino H. Enchanced TGF-(3/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor. Clin Ex Nephrol 11: 77-87, 2007.
45. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 97: 7667-7669, 2000.
46. Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cersosimo E, Defronzo RA, Coletta DK, Siriwijitkamol A, Musi N. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 57: 2595-2602, 2008.
47. Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro-Gonzalez JF. Pathogenic perspective for the role of inflammation in diabetic nephropathy. Clin Sci 116: 479-492, 2009.
48. Schernthaner G. Kidney disease in diabetology: lessons from 2007. Nephrol Dial Transplant 23: 1112-1115, 2008.
49. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46: 854-859, 1997.
50. Sharma K, Ziyadeh FN. Renal hypertrophy is associated with upregula-tion of TGF-beta1 gene expression in diabetic B rat and NOD mouse. Am J Physiol Renal Fluid Electrolyte Physiol 267: F1001-F1094, 1994.
51. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38: 1077-1081, 1987.
52. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukocyte Biol 76: 14-519, 2004.
53. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814- 1818, 1993.
54. Ziyadeh FN, Snipes ER, Watanabe M, Alvarez RJ, Goldfarb S, Haverty TP. High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am J Physiol Renal Fluid Electrolyte Physiol 259: F704-F714, 1990.